Biomarkers for critical conditions
The biomarkers developed by SphingoTec address critical conditions that are a global healthcare burden. Worldwide about 49 million people suffer from sepsis (1) and 13 million from acute kidney injury (2). They are life-threatening diseases with high hospitalization costs. The innovative biomarkers aim at providing actionable information for improved patient management.
Kidney function biomarker
Proenkephalin A 119-159 (penKid*)
PenKid, is a dynamic biomarker for the real-time assessment of kidney function. penKid is a blood-based alternative reflecting true GFR that is applicable in routine laboratory testing independent of inflammation and common comorbidities.
Endothelial function biomarker
Bioactive Adrenomedullin 1-52 (bio-ADM*)
Bio-ADM is a dynamic biomarker for the real-time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock, and subsequent organ failure in critically ill patients.
*Disclaimer
Sphingotest® penKid®, and sphingotest® bio-ADM® are offered for in vitro diagnostics. “penKid” and “bio-ADM” represent the analytes Proenkephalin A 119-159 and bioactive Adrenomedullin 1-52, respectively.
Reference Literature
(1) Rudd et al. (2020), Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study, The Lancet.
View the paper
(2) Mehta et al. (2015), International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet.
View the paper